(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Venus shines at its best in spring and summer 2026 — here's what to look for - 2How to see the Ursids, the final meteor shower of 2025
- 3Dental, Vision, and Hearing Inclusion in Senior Protection.
- 4Brazil expands pesticide packaging reverse logistics
- 5Why are NASA's Artemis astronauts wearing orange? What are they bringing to space? What to know about the preparation for their moon mission.
- Step by step instructions to Integrate Lab Precious stones into Special Adornments Pieces
- Massive supernova explosion may have created a binary black hole
- US FDA declines to approve Corcept's drug for rare hormonal disorder
- 25 Years Ago, Audi's Rosemeyer Concept Was A Steampunk Supercar With A Massive Engine
- Car Investigation: A Survey of \Past the Outside\ Car
- Iran fires one of largest barrages in weeks ahead of Passover
- RFK Jr. succeeds in changing hepatitis B recommendation | The Excerpt
- 4 Family SUVs: Joining Solace and Style
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
